Trial · NCT03288324
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Oral Clearance (CL/F) (Cohort 1 Only) | Cohort 1 | 28.4 | Geometric Coefficient of Variation 23.5 | (L/hr) | |
| Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score | Cohort 1 & Cohort 2 | Baseline | 16.55 | Standard Deviation 8.03 | score on a scale |
| Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score | Cohort 1 & Cohort 2 | Week 4 | 10.91 | Standard Deviation 8.4 | score on a scale |
| Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score | Cohort 1 & Cohort 2 | Week 8 | 8.64 | Standard Deviation 7.8 | score on a scale |
| Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score | Cohort 1 & Cohort 2 | Week 24 | 8.82 | Standard Deviation 7.9 | score on a scale |
| AUCt (Cohort 1 Only) | Cohort 1 | 176 | Geometric Coefficient of Variation 23.5 | (ng.hr/mL) | |
| Cmax (Cohort 1 Only) | Cohort 1 | 51.7 | Geometric Coefficient of Variation 21.6 | (ng/mL) | |
| Tmax (Cohort 1 Only) | Cohort 1 | 1 | Full Range .5 to 2 | hr | |
| Vz/F (Cohort 1 Only) | Cohort 1 | 85.2 | Geometric Coefficient of Variation 25.6 | L | |
| Half-life of Tofacitinib (Cohort 1 Only) | Cohort 1 | 2.1 | Standard Deviation 0.321 | hr | |
| Safety of Tofacitinib: Total Number of Adverse Events is Reported (Cohorts 1 and 2) | Cohort 1 and 2 | 73 | total adverse events | ||
| Steroid Dose Comparison at 72 Weeks | Cohort 1 & Cohort 2 | 7.5 | Standard Deviation 3.54 | mg | |
| Change in SLE Disease Activity Index (SLEDAI) Score | Cohort 1 & Cohort 2 | Baseline | 7.1 | Standard Deviation 1.96 | score on a scale |
| Change in SLE Disease Activity Index (SLEDAI) Score | Cohort 1 & Cohort 2 | Week 24 | 4 | Standard Deviation 1.6 | score on a scale |
| Change in SLE Disease Activity Index (SLEDAI) Score | Cohort 1 & Cohort 2 | Week 72 | 4.4 | Standard Deviation 2.41 | score on a scale |
| Change in SKINDEX Score | Cohort 1 & Cohort 2 | Baseline | 37.6 | Standard Deviation 24.16 | score on a scale |
| Change in SKINDEX Score | Cohort 1 & Cohort 2 | Week 24 | 24.3 | Standard Deviation 28.67 | score on a scale |
| Change in SKINDEX Score | Cohort 1 & Cohort 2 | Week 72 | 25.5 | Standard Deviation 30.71 | score on a scale |
| Change in Patients Global Assessment Score | Cohort 1 & Cohort 2 | Baseline | 2.7 | Standard Deviation 1.47 | score on a scale |
| Change in Patients Global Assessment Score | Cohort 1 & Cohort 2 | week 24 | 1.3 | Standard Deviation 1.2 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03288324/results